Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by MeiraGTx MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress October 22, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease October 15, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference October 09, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results August 12, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi August 12, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports First Quarter 2024 Financial and Operational Results May 09, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Participate in Upcoming Investor Conferences April 24, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference April 18, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates March 14, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals February 13, 2024 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million December 21, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Participate in Upcoming Investor Conferences November 21, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Third Quarter 2023 Financial and Operational Results November 14, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities October 30, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress October 24, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports Second Quarter 2023 Financial and Operational Results August 10, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology August 01, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing July 19, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia June 27, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, June 22, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting May 16, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports First Quarter 2023 Financial and Operational Results May 11, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces $60 Million Private Placement of Ordinary Shares May 03, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting April 21, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Participate in Upcoming Investor Conferences April 20, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results March 14, 2023 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia December 13, 2022 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 December 08, 2022 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx to Participate in Upcoming Investor Conferences November 22, 2022 From MeiraGTx Via GlobeNewswire Tickers MGTX MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. November 10, 2022 From MeiraGTx Via GlobeNewswire Tickers MGTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
